ERBB2 and breast carcinoma: In 2013 a genomic technique, gene expression profiling, was approved for use within the UK NHS for a defined group of patients with early stage ER/PR+, HER2-and LN- breast cancer (National Institute for Health and Care Excellence, 2018).